Mission EB

In the first large-scale stem cell clinical trial in epidermolysis bullosa (EB), the “MissionEB” study, CORDStrom was investigated in a double-blinded, randomized, placebo-controlled pivotal trial to evaluate the safety and efficacy of CORDStrom in 30 pediatric patients in the UK with intermediate and severe RDEB using a novel crossover clinical trial design. Topline results showed CORDStrom was easily administered, well tolerated, with no serious adverse effects related to treatment, and there were beneficial effects with respect to itch, pain, disease severity and quality of life measures.